Gilead Sciences Files 8-K on Financials
Ticker: GILD · Form: 8-K · Filed: Feb 11, 2025 · CIK: 882095
Sentiment: neutral
Topics: financial-results, disclosure
Related Tickers: GILD
TL;DR
GILD dropped an 8-K on Feb 11th detailing financial results. Check it out.
AI Summary
On February 11, 2025, Gilead Sciences, Inc. filed an 8-K report to disclose information regarding its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial performance. Gilead Sciences, Inc. is incorporated in Delaware and headquartered in Foster City, California.
Why It Matters
This 8-K filing provides investors with crucial updates on Gilead Sciences' financial health and operational results, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial disclosure filing and does not indicate any immediate or significant risks.
Key Players & Entities
- GILEAD SCIENCES, INC. (company) — Registrant
- February 11, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Foster City, California (location) — Principal Executive Offices
- 650 - 574-3000 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Gilead Sciences, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on February 11, 2025.
Where is Gilead Sciences, Inc. headquartered?
Gilead Sciences, Inc. is headquartered at 333 Lakeside Drive, Foster City, California, 94404.
What is the state of incorporation for Gilead Sciences, Inc.?
Gilead Sciences, Inc. is incorporated in Delaware.
What is the telephone number for Gilead Sciences, Inc.?
The telephone number for Gilead Sciences, Inc. is 650-574-3000.
Filing Stats: 684 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2025-02-11 16:04:28
Key Financial Figures
- $0.001 — ch registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select
Filing Documents
- gild-20250211.htm (8-K) — 32KB
- exhibit991earningspressrel.htm (EX-99.1) — 709KB
- gilead_transparentxlogoxsta.jpg (GRAPHIC) — 37KB
- 0000882095-25-000003.txt ( ) — 955KB
- gild-20250211.xsd (EX-101.SCH) — 2KB
- gild-20250211_lab.xml (EX-101.LAB) — 21KB
- gild-20250211_pre.xml (EX-101.PRE) — 12KB
- gild-20250211_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 11, 2025 , Gilead Sciences, Inc., a Delaware corporation ("Gilead"), issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles ("GAAP") and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 11, 12 and 13 of the press release filed as Exhibit 99.1 to this report. The information in Item 2.02 and Item 9.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. Section 9 - FINANCIAL STATEMENTS AND EXHIBITS
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on February 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GILEAD SCIENCES, INC. (Registrant) /s/ ANDREW D. DICKINSON Andrew D. Dickinson Chief Financial Officer Date: February 11, 2025 Exhibit Index Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on February 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)